Who
Steven Gannon
Director
Company insider
Files Form 4 as: Director, Xenon Pharmaceuticals; Director, Fusion Pharmaceuticals.
In numbers
- Trades disclosed
- 52
- Buys
- 6
- Sells
- 3
- Bought
- $229K
- Sold
- $1.9M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 21 May 2015
- Last trade
- 11 Aug 2026
- Last filed
- 13 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Aug 2026filed 13 Aug 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $641K10,000 at $64.06 | filing |
| 11 Aug 2026filed 13 Aug 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $641K10,000 at $64.06 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $76K1,416 at $53.41 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $76K1,416 at $53.41 | filing |
| 12 May 2026filed 13 May 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $26K3,500 at $7.38 | filing |
| 12 May 2026filed 13 May 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 12 May 2026filed 13 May 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 12 May 2026filed 13 May 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $26K3,500 at $7.38 | filing |
| 5 Jun 2025filed 6 Jun 2025 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,012 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,645 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $913 at $30.48 | filing |
| 14 May 2025filed 16 May 2025 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,144 at $0.00 | filing |
News
Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)XENE · dailypolitical.com · 18 Oct 2026Head to Head Survey: Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR)XENE · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Steven Gannon; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.